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Abstract
Background: New molecular methods of detecting Clostridium difficile infection (CDI) provide the routine lab with
a sensitive random access method to produce results that are available in a shorter time than traditional methods.
Methods: In this prospective study a total of 989 stool specimens were tested over a period of 16 months in parallel
using two isothermal amplification assays, AmpliVue® (Quidel) and Illumigene® (Meridian) and the results compared to
those from toxigenic culture. In addition all specimens were tested using a cytotoxic cell neutralisation assay (CCNA)
and three different Real-time PCR targeting a C. difficile-specific 16S rDNA sequence or the toxin genes tcdA, tcdB/
tcdB027 or cdtB.
Results: AmpliVue® was positive in 242 (24.5 %) and Illumigene® in 228 (23.1 %) specimens. 167 (16.9 %) specimens
were positive in toxigenic culture. Real-time-tcdA and -tcdB PCR was positive in 211 (21.3 %) specimens, Real-time-cdtB
PCR was positive in 101 (10.2 %) specimens and C. difficile-PCR (16S rDNA) in 267 (27.0 %) specimens.
Conclusions: The respective sensitivity, specificity, positive predictive value and negative predictive value compared to
toxigenic culture were 91, 89, 62 and 98 % for AmpliVue® and 91, 91, 67 and 98 % for Illumigene®.
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Background
Clostridium difficile infection (CDI) is the leading cause
of health-care associated diarrhoea most frequently associ-
ated with antecedent antibiotic therapy. The incidence of
CDI in Europe is rising steadily and has considerable influ-
ence on patient morbidity and mortality [1]. The clinical
presentation varies widely from mild, watery diarrhoea to
pseudomembranous colitis, toxic megacolon and sepsis [2]
and in addition recurrent CDI has become a major problem
possibly related to binary toxins as virulence factors [3, 4].
Rapid diagnosis forms a cornerstone for patient manage-
ment and early isolation, and adequate (antibiotic) therapy
of infected patients may reduce transmission and disease
severity [5, 6]. The laboratory detection of Clostridium
difficile is increasingly focused on toxin detection as routine
toxigenic culture has a long turnaround time [7]. A C.
difficile-specific glutamate dehydrogenase antigen detection
assay can be used as a sensitive screening test but has a low
specificity and thus requires confirmation, usually by detec-
tion of one or both toxin genes [8] or antigen detection
using an EIA, which has a low sensitivity. Isothermal ampli-
fication assays are easy to use, have low hands on and turn-
around times and are highly sensitive [9–12]. European and
American guidelines have recommended a two-step testing
algorithm for the laboratory diagnosis of CDI consisting of
a sensitive antigen test followed by a more specific con-
firmatory test [13, 14] although more recent guidelines have
recommended the use of NAATs as stand-alone tests [15].
Due to insufficient data isothermal amplification assays
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have not generally been included in the recommendations
concerning NAAT [15]. A recent meta-analysis of pub-
lished data for loop-mediated isothermal amplification
shows the accuracy of this type of isothermal amplification
method [9]. The optimal combination of tests is largely
dependent on the local conditions and resources. In this
large prospective study we compared the performance of
two different isothermal amplification assays (AmpliVue®,
helicase dependant amplification and Illumigene®, loop-
mediated isothermal amplification) with toxigenic culture
and additionally with an in-house Real-time PCR and
cytotoxic cell neutralisation assay in a routine diagnostic
laboratory setting.
Methods
From January 2013 to April 2014 consecutive liquid
stool specimens received by the laboratory with a re-
quest for C. difficile-toxin assay from hospital wards and
out-patient departments of three tertiary care hospitals
were included in the study and fully evaluated. The
persons performing the tests were blinded to the results
of the other tests. The study was approved by the ethics
committee of the medical faculty of the Heinrich-Heine
University of Düsseldorf. Specimens were tested by two
commercial isothermal amplification assays, toxigenic
culture (TC), cytotoxic cell neutralisation assay (CCNA)
and by Real-time PCR (Real-time-tcd PCR) targeting
gene sequences for toxin A, B, and B027 (a sequence
incorporating a mutation found in the tcdB gene in ribo-
type 027 strains), binary toxin B (Real-time-cdtB PCR)
and a C. difficile-specific 16S fragment (Real-time-16S
PCR). In previous work we found no C. difficile strains
with discordant cdtA and cdtB results and thus the cdtB
gene was used as a marker for the presence of both
binary toxin genes (unpublished data). Sequencing of the
slpA gene was performed on all available C. difficile iso-
lates. The reference method was toxigenic culture.
All specimens were tested according to the manufac-
turers’ instructions within 48 h after delivery to the labora-
tory. If necessary the specimens were stored at 4 °C until
testing was performed. In brief, the Illumigene® assay em-
ploys loop-mediated isothermal DNA amplification
(LAMP) to detect a gene segment of the tcdA gene in the
pathogenicity locus (PaLoc) present in all known toxigenic
C. difficile strains. The AmpliVue® assay utilizes helicase-
dependant amplification (HDA) for the detection of a con-
served sequence of the tcdA gene. Positive and negative
controls for both assays were provided by the manufac-
turers and were performed weekly. All stool specimens
were cultured for C. difficile by inoculating a portion of
the stool sample onto Clostridium difficile selective agar
(bioMérieux, Germany) and incubating under anaerobic
conditions for 48 h. Growth of colonies suspected to be
C. difficile were identified by MALDI-ToF (Vitek® MS,
bioMérieux, Germany). C. difficile isolates were stored
in glycerine stocks at −80 °C and re-cultured on blood
agar for slpA sequencing.
CCNA was performed by re-suspending approximately
100 μl of fresh stool in 500 μl normal saline and centri-
fuging at 850 g for 1 min. Thereafter the supernatant
was passed through a 0.2 μm filter and 50 μL of two
dilutions, 1:5 and 1:50 in sterile normal saline, added in
duplicate to four wells containing a monolayer of BGM
(Buffalo Green Monkey) cells (Sigma-Aldrich, Munich).
To one well of each dilution polyclonal anti-toxin
antibody was added (Techlab, Blacksberg, USA). A cyto-
pathic effect only in the well without anti-toxin was
interpreted as a positive result. Toxigenic culture was
performed by adding C. difficile culture supernatant to
the CCNA instead of stool and results were interpreted
in a similar procedure.
DNA extraction from stool specimens was performed
by mixing approximately 10 μl of the stool specimen in
500 μl PBS and centrifuging at 850 g for 1 min. A 200 μl
aliquot of the supernatant was extracted using the DNA
tissue kit and EZ1 BioRobot (Qiagen, Germany) and
eluted in 100 μl. The eluates were kept at −20 °C until
tested.
For slpA sequencing 2.5 μl DNA eluate was added to 1 μl
Peqgold Hot-Start mastermix (Peqlab, Erlangen), 20.5 μl
distilled water and 1 μl (3 μM) primers slpA 19 and slpA 22
(Table 1). The PCR was performed on an Eppendorf Mas-
tercycler pro thermocycler (Wesseling-Berzdorf, Germany)
as follows: 95 °C for 5 min and subsequently 35 cycles com-
prising 95 °C for 20 s and 55 °C for 180 s, then incubation
at 74 °C for 30 s. A final step at 74 °C for 5 min completed
the PCR. The amplified DNA was sequenced by the Sanger
method in the university molecular biology core facility
(BMFZ, Biologisch-Medizinisches Forschungzentrum).
For all Real-time PCRs the mastermix per specimen
was composed of 12.5 μl Qiagen Mastermix and 2.5 μl
(3 μM) each of forward and reverse primers (Table 1),
2.5 μl probe and 2.5 μl H2O. 2.5 μl from the DNA-eluate
were added to the mastermix and heated at 50 °C for
10 min and then 95 °C for 10 min and thereafter placed
in a thermocycler (BioRad, München) for 44 cycles com-
prising 95 °C for 15 s and 60 °C for 60 s.
The sequences for the primers and probes for the
Real-time PCR and slpA analysis are shown in Table 1.
Results
A total of 989 stool specimens from 828 patients were
included in the study. The number of positive specimens
in toxigenic culture was 167 (17 %). The AmpliVue® assay
was positive in 242 (25 %) specimens and Illumigene®
assay in 228 (23 %) specimens. Real-time-tcd PCR was
positive in 211 (21 %) specimens (of these 79 (8 %) were
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positive for the tcdB027 gene) and C. difficile-16S-PCR
was positive in 267 (27 %) specimens.
Isothermal amplification assay results discrepant to toxi-
genic culture are shown in Tables 2 and 3. A total of 90
(9 %) specimens tested with AmpliVue® and 75 (8 %) speci-
mens tested with Illumigene® were positive by isothermal
amplification but negative in the toxigenic culture (i. e. false
positive). Sixty three of these specimens were positive in
both isothermal amplification methods. On the other hand
15 (2 %) specimens tested with AmpliVue® and 14 (1 %)
specimens tested with Illumigene® were negative in isother-
mal amplification but positive in the toxigenic culture (i. e.
false negative). Of these 12 specimens were negative in both
isothermal amplification assays. C. difficile strains in which
no toxin production was detected in bacterial culture
supernatants were classified non-toxigenic strains. 20 of 34
stool specimens containing non-toxigenic strains were posi-
tive in the AmpliVue® assay and 19 strains were positive in
the Illumigene® assay. The respective sensitivity, specificity,
positive predictive value (PPV) and negative predictive
value (NPV) for the isothermal amplification assays com-
pared to toxigenic culture were 91, 89, 62 and 98 % for
AmpliVue® and 91, 91, 67 and 98 % for Illumigene®. The
sensitivity, specificity, PPV and NPV for Real-time tcd PCR
compared to toxigenic culture were 91, 93, 73 and 98 %
respectively.
For general epidemiological purposes and to determine
if there was any correlation between strain type and the
results of isothermal amplification or toxigenic culture
all cultures were typed by slpA-sequencing. Of the C.
difficile strains 171 were typable by slpA sequencing the
distribution of which is shown in Fig. 1. Three slpA
types made up the majority (69 %) of the strains: the
most common slpA type was gc8 (63 specimens, 37 %)
(associated with ribotype 027 [16]); followed by gr (29
Table 2 Discrepant results for isothermal amplification: false
positive specimens
N AmpliVue® Illumigene® Culture TC Real-time-tcd PCR 16S PCR
17 + + + - + +
1 + + + - - +
30 + + - - + +
4 + + - - - +
11 + + - - - -
1 + - + - - +
1 + - - - + +
3 + - - - - +
18 + - - - - -
1 - + + - + +
2 - + - - + +
8 - + - - - -
1 + invalid + - + +
1 + invalid - - - +
1 + invalid - - + +
1 + invalid - - - -
1 Invalid + - - - -
TC, toxigenic culture
Table 1 Primers and probes
Gene Primers/Probes PCR-product (bp) Acc-number Gene region (bp)
tcdA tcdA F: 5-´ATTCCAATACAAGYCCTGTAGAAAA-3´ 85 AM180355 796102–796186
tcdA R: 5- TTTATGTATTCAAGARCAATATCACTGACT-3´
tcdA-S: 5´Fam-RATTTACATTTTGTATGGATAGGTGGAG-BHQ-1-3´
tcdB tcdBF: 5´-AACAGGTGTATTTAGTACAGAAGATGGATT-3´ 85 AM180355 793077–793161
tcdBR: 5´-AATTGCTTCTCCTTCTAGGTTTTCAT-3´
tcdB-S: 5´-Hex-AAATATTTTGCCCCAGCTAATACACTT-BHQ-1-3´
tcdB027a tcdBF: 5´-AACAGGTGTATTTAGTACAGAAGATGGATT-3´ 85 FN665654 708928–709012
027tcdBR*: 5´-AATTGCTTCCCCCTCTAGATTTTCAT-3´
027tcdB-S:5´-Hex-AAATATTTTGCTCCAGCAGATACACTT-BHQ-1-3´
16S CdF: 5´-TGTACACACGGATAACATACCGAAA-3´ 131 AM180355 125189–125289
CdR:5´-CCGTTACCTTACCAACTAGCTAATCA-3´
CdS5´-Fam-CATCTCTTGAATATCAAAGGTGAGCCAGTACAGG-BHQ-1-3´
cdtB cdtBfor: 5´GATGATCCATTTATCCCAAATAACAA-3´ 132 FN665654 2833044–2833175
cdtBrev:5´GTCCTTAATAGTATATCCATTTCGTTCATATG-3´
cdtBS:5´Hex-TTCTTTGACCCAAAGTTGATGTCTGATTGGG-BHQ-1-3´
slpA (Kato et al. 2004) slpAcom22 : 5'-GCWGTYTCTATTCTATCDTYWCC-3' 23 AM180355 3253526–3254737
slpAcom19 : 5'-GTTGGGAGGAATTTAAGRAAtG-3' 22
aBolded bases represent a difference from the standard tcdB primer or probe
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specimens, 17 %; 27 of which were gr-01 and 2 were gr-
04) and hr (25 specimens, 15 %; 19 of which were hr-01, 4
were hr-02, 1 was hr-05 and 1 was hr-06). 8 (5 %) speci-
mens were typed as 078–01 or kr03. All other slpA types
were represented by less than 8 specimens each. 14 speci-
mens of the 171 specimens analysed by slpA sequencing
were atoxigenic as they were neither positive in TC nor in
Real-time-tcd PCR. Atoxigenic slpA types were xr and 078
(3 specimens each) and one strain each was nc, cr, ac, fr.
Of the 79 specimens positive in the tcdB027 Real-time
PCR 61 specimens were available for slpA-typing. 57
(93 %) of these specimens were type gc8 and of 63 gc8
types 57 (90 %) were tcdB027-positive.
The binary toxin gene (cdtB-PCR) was detected in 87
specimens. A correlation between Real-time tcdB027 PCR
and cdtB PCR positivity was high (70 of the 87 binary
toxin positive specimens (80 %) were Real-time-tcdB027
PCR positive).
Discussion
To our knowledge this is the largest reported study com-
paring the isothermal amplification assays from AmpliVue®
and Illumigene® with a Real-time PCR in reference to
toxigenic culture. A study reported by Deak et al. directly
comparing the AmpliVue® assay and a Real-time PCR assay
by Simplexa® (Simplexa TM, Focus Diagnostics) with the
Illumigene® assay in a sample size of 200 found a sensitivity
and specificity of 96 % and 100 %. Other recent studies with
a lower number of specimens using TC as reference
method have also revealed high sensitivities and specificities
for AmpliVue® and Illumigene® [10–12, 17, 18].
In general molecular tests have many advantages: They
are easy to perform and often associated with high sensitiv-
ity and specificity. Nevertheless there are some disadvan-
tages. Firstly, the assays are performed in stool containing a
large amount of extraneous DNA which may interfere with
the detection [11]. Recent studies however have not shown
much cross reactivity [19, 20]. Secondly, the mere presence
of toxin genes is not proof of toxin expression. Therefore
only patients with an appropriate clinical suspicion of CDI
should be tested by the laboratory [11, 21] since the car-
riage of C. difficile, even toxigenic strains, is not necessarily
diagnostic of disease or in itself an indication for therapy
[22, 23]. In settings with a low prevalence of CDI the low
positive predictive value of the isothermal tests as shown in
this study may lead to a rather high number of laboratory
diagnoses of CDI, in which perhaps another cause for the
diarrhoea is present. This is especially important in clinic-
ally complicated cases, in which multiple factors may be
relevant.
The relatively low PPV in our study compared to that of
Hong et al. may possibly be due to a lower sensitivity of
the reference method in our study. The number of speci-
mens positive in 16S-PCR (106) that were C. difficile
culture-negative would support this hypothesis, however
the detection of DNA from C. difficile alone does not
necessarily relate to the presence of viable bacteria and
since the CCNA was negative in all these cases it would
seem probable that if indeed bacteria were present and
viable, they were not producing significant amounts of
toxin and therefore not causing CDI. This raises the im-
portant question as to the clinical usefulness of such
highly sensitive methods to detect CDI and if NAAT
methods may in fact not overcall CDI. A contrary view is
that since CDI is thought to be essentially underdiagnosed
[24, 25], the high sensitivity of isothermal amplification
assays may contribute to a better detection of disease.
In 34 (3.4 %) specimens the toxigenic culture was nega-
tive despite a positive culture for C. difficile indicating non
toxin-producing strains. In comparison the Real-time-tcd
PCR was positive in 56 cases, in which toxigenic culture
was negative resulting in a specificity and PPV of 93 and
73 %. According to Buchan et al. false positive results can
occur due to the presence of non-viable bacteria or
residual DNA or because the isothermal amplification tests
have a lower level of detection than toxigenic culture (i. e.
true positive). As a control in their study they used another
PCR targeting a different region of the C. difficile chromo-
some than that targeted by the isothermal amplification
assay, the results of which confirmed the results of the
Table 3 Discrepant data for isothermal amplification: false
negative specimens
N AmpliVue® Illumigene® TC Real-time-tcd PCR Real-time 16S PCR
1 - - + + +
2 - - + - +
9 - - + - -
2 - + + - +
1 - + + + +



















Fig. 1 Prevalence of slpA types in the study isolates. All cultures
were subjected to typing by determining the slpA sequence as
described in the methods
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latter. This would support the purported higher sensitivity
of the isothermal amplification assay [26]. Following this
argument the performance of the isothermal amplification
assays in terms of true specificity and PPV would be better
if the reference method in our study was more sensitive.
In the present study we found only one minor difference
between the two isothermal assays: A higher number of
invalid results (26 specimens) were obtained using the
Illumigene® assay; whereas only 11 specimens were invalid
using the AmpliVue® assay. The relatively high number of
non-evaluable tests using Illumigene® was due to sample
overloading at the beginning of the study period, which
improved with experience and in the latter half of the
study was negligible. Furthermore Illumigene® invalid re-
sults are known to be caused by blood-containing samples
[27, 28]. In this study very few patients presented with
bloody diarrhoea (data not shown). However we were able
to confirm this in 2 macroscopically bloody samples. This
would be a disadvantage of the assay for patients with
severe CDI and bloody stools unless an additional DNA-
purification step is added prior to testing.
To evaluate the practicality of the isothermal amplifi-
cation assays the number of steps, hands on time and
turnaround time were determined. Both are equivalent
in terms of practicality in the routine laboratory. Each
assay had 6 (Illumigene®) and 7 (AmpliVue®) steps with
hands on time for 10 specimens of 14 min (Illumigene®)
and 12 min (AmpliVue®) and total turnaround time was
64 and 92 min respectively.
Conclusion
This study contributes data towards the determination of
the value of isothermal amplification as a diagnostic tool
for CDI. Both isothermal methods are easy to use, deliver
reliable results with a rapid turn-around time and have a
high sensitivity compared to other molecular methods. A
high negative predictive value of 98 % was demonstrated
for both assays, which provides a rapid reliable result to
clinicians treating patients with suspected CDI and
diarrhoea enabling a de-escalation of empiric therapy. For
laboratories dealing with a small number of CDI-requests
the option of a single step random access diagnostic
method in terms of personnel efficiency is probably cost
effective. Both tests are useful for the detection of C.
difficile with up to 10 specimens per run.
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